Analysis of 佰澤醫療 (02609.HK) - Hot Stock Status and Company Profile

佰澤醫療 (02609.HK) is a Chinese oncology medical group listed on HKEX, featured on the HK hot stock list [0]. It showed strong initial listing performance but faced mid-term loss expansion [6]. Conflicting data exists regarding its current status: some sources suggest possible delisting [1], while recent operational data indicates it may still be active [3-7].

佰澤醫療 is a Chinese oncology medical group listed on HKEX on June 23, 2025 [3]. It operates in the medical sector, focusing on oncology services.

• IPO price: 4.22 HKD [3]
• First-day close:6 HKD (up 42.2% from IPO) [3]
• Turnover on listing day:117 million HKD [3]
• Public offering oversubscribed:25.92x [5]
• 1-hand success rate:20% [5]

• Mid-term 2025 revenue:575 million RMB (+0.7% YoY) [6]
• Mid-term 2025 net loss:27.62 million RMB (expanded from previous period) [6]

Featured on the HK hot stock list (东方财富App人气榜) [0].

Conflicting information about current listing status: some sources mention possible delisting [1], while recent data (as of mid-2025) exists [3-7].

1. Strong initial investor interest contrasts with ongoing financial losses.
2. Sector volatility in the medical industry may impact its performance.
3. Need for verification of current listing status due to conflicting reports.

• Financial loss expansion [6]
• Possible delisting concerns [1]
• Sector regulatory and market fluctuations

• Strong initial market reception (oversubscribed IPO) [5]
• Growth potential in the oncology medical sector

Investors should verify the current listing status of 佰澤醫療 (02609.HK) and monitor its financial improvements. The company has mixed performance indicators, with initial strength offset by recent losses.